Wise Combi Pheri Injection #1

Adult dosage

Prior to administration, the partition should be opened to mix Solution A and Solution B. The maximum dosage should be 1 to 1.5 g of total amino acids per kg of body weight per day. The infusion rate should not exceed 2.3 mL per hour (equivalent to glucose 0.25 g/kg and amino acids 0.04 g/kg), and it is preferable to administer it intravenously over 12 to 24 hours.

Children's dosage

In children, elderly patients, and patients with high protein requirements such as burn victims, dosage and infusion rates should be adjusted.

This medication must be used strictly according to a physician's instructions. When used with intravenous calcium-containing preparations, precipitates may form if mixed with ceftriaxone, so the same infusion device should not be used simultaneously. Patients with allergic reactions or specific electrolyte abnormalities, as well as those with heart, liver, or kidney diseases, should not use this medication. Pregnant or nursing women should exercise caution and use this medication under the physician's judgment, as safety has not been established. In children, especially infants under 2 years of age, safety has not been confirmed, and its use should be avoided. Elderly patients may have decreased bodily function, so the infusion rate should be slow, and the dosage should be adjusted. This medication contains a high concentration of glucose, which may cause hyperglycemia or electrolyte imbalance, so periodic monitoring of blood glucose and electrolyte status during administration is necessary. Sudden discontinuation of administration may lead to hypoglycemia, so it should be reduced gradually. If any abnormal symptoms or allergic reactions occur during administration, use should be stopped immediately and consult a physician. This medication may cause venous irritation or thrombophlebitis during intravenous injection, so the injection site should be monitored closely. In cases of excessive administration, acidosis, fluid overload, electrolyte imbalance, etc., may occur, so dosage and infusion rates must be strictly adhered to. This medication should be properly mixed before administration and used quickly; any remaining solution after opening should not be reused. Storage should be at room temperature, and solutions that are damaged or discolored should not be used. When mixing this medication with other drugs, compatibility must be verified, and it should be mixed in a sterile state. Patients with a history of myocardial infarction are advised against using this medication.

Serious side effects

Urticaria, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, paleness, severe rash with fever, blisters, skin peeling, pain in oral/ocular mucosa, difficulty breathing or shortness of breath, asthma attack, respiratory abnormalities accompanied by cough and fever, jaundice (yellowing of skin or eyes), profound malaise, sudden and severe headache, thunderclap headache, seizures, altered consciousness, visual disturbances, paralysis, urinary issues

Mild side effects

• Urticaria
• rash
• nausea
• vomiting
• chills
• fever
• headache
• chest discomfort
• palpitations
• tachycardia

This medication should be stored in a sealed container to prevent air and moisture from entering, and it is safe to store at a temperature between 1 degree and 30 degrees Celsius. This storage method maintains the medication's effectiveness and prevents deterioration.

Appearance

A light yellow transparent liquid filled in a transparent plastic container with internal partitions.

Package unit

550 mL/bag, 1100 mL/bag